STUDY DESIGN 

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that significantly impacts patients' quality of life (QoL).¹ Individuals with HS often experience comorbidities, including psychiatric conditions such as depression and anxiety, with recent findings indicating they are about twice as likely to develop these disorders compared to those without HS.¹ Secukinumab has shown sustained efficacy in moderate to severe HS in the SUNSHINE and SUNRISE phase 3 trials, improving QoL while maintaining a favorable safety profile over one year.¹

The post-hoc analysis of pooled data from these trials assessed psychiatric comorbidities at baseline and through week 52 in patients treated with secukinumab.¹ In both trials, patients were randomized to receive subcutaneous secukinumab 300mg every 2 weeks (SECQ2W) or 4 weeks (SECQ4W), or placebo for 16 weeks.¹ After this period, placebo patients switched to secukinumab while those on SECQ2W and SECQ4W continued their treatment until week 52.¹ A total of 1,084 patients were enrolled, with a mean age of 36.2 years and 56.3% being female.¹

The analysis assessed the frequency of psychiatric comorbidities at baseline, focusing on reports of "psychiatric disorder," "depression," and "anxiety," along with the concomitant use of medications for these conditions during the trial.¹

The impact of secukinumab on psychiatric symptoms was assessed using 2 patient-reported outcome measures.¹ Mood was evaluated through the "anxiety/depression" item of the European QoL 5-Dimension (EQ-5D) questionnaire up to week 52.¹ Emotional impact was measured using the HS Symptom and Impact Diary (HSSID), where patients rated the negative impact of HS on their emotions over the past 24 hours on a 0-3 scale.¹ Incidence of new or worsening psychiatric adverse events was also reported through week 52.¹ All analyses were exploratory with no statistical

STUDY DESIGN 

A 2007-2008 assessment of atopic dermatitis (AD) severity and height revealed that adolescents with moderate to severe AD had significantly higher odds of having a height <25th percentile on Center for Disease Control (CDC) growth reference chart.¹ In particular, children with AD and in the ≤25th height percentile have a greater risk of having low bone mineral density and alkaline phosphatase (ALP) levels.¹ The underlying mechanisms of this phenomenon remain unclear but may be linked to chronic sleep disruption associated with AD, the use of oral and topical glucocorticoids, and the effects of prolonged inflammation.¹

Dupilumab was previously shown to significantly increase the levels of bone ALP in serum compared to placebo in children aged 6 to 11 with moderate-to-severe AD enrolled in a phase 3 trial and it’s open-label extension (OLE) study.¹ In the LIBERTY-AD PEDS trial, the proportion of children aged 6 to 11 years with severe AD and lower stature who reached a ≥5-percentile improvement in height following 16 weeks of treatment with dupilumab compared to those in the placebo group was reported.¹

LIBERTY-AD PEDS was a double-blind, randomized, placebo-controlled study that enrolled 304 children aged 6 to 11 years with severe AD.¹ Participants were randomized 1:1 to receive 300mg dupilumab every 4 weeks or placebo, in addition to mild or moderately potent topical corticosteroids.¹ The height and weight of the participants were collected at baseline and at week 16 in a post-hoc analysis.¹